Sandoz Lines Up Higher-Strength Adalimumab In Europe

Filing For 100mg/ml Version Of Hyrimoz Biosimilar Rival To Humira Accepted By EMA

 
• By Dave Wallace
  
Three Player Chess Board
Could Europe soon become a three-player market for 100mg/ml adalimumab biosimilars? • Source: Shutterstock

More from Biosimilars

More from Products